• Users Online: 290
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 


 
 Table of Contents  
IMAGE IN HEMATOLOGY
Year : 2021  |  Volume : 12  |  Issue : 4  |  Page : 236-237

Primary cutaneous diffuse large B-cell lymphoma, leg type


1 Department of Medical Oncology, Amrita Institute of Medical Science and Research Center, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India
2 Department of Pathology, Amrita Institute of Medical Science and Research Center, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India

Date of Submission07-Feb-2021
Date of Decision30-Mar-2021
Date of Acceptance10-Apr-2021
Date of Web Publication18-Jan-2022

Correspondence Address:
Dr. Keechilat Pavithran
Department of Medical Oncology, Amrita Institute of Medical Science and Research Center, Amrita Vishwa Vidyapeetham, Kochi, Kerala
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/joah.joah_11_21

Rights and Permissions

How to cite this article:
Pavithran K, Nair IR. Primary cutaneous diffuse large B-cell lymphoma, leg type. J Appl Hematol 2021;12:236-7

How to cite this URL:
Pavithran K, Nair IR. Primary cutaneous diffuse large B-cell lymphoma, leg type. J Appl Hematol [serial online] 2021 [cited 2022 Sep 25];12:236-7. Available from: https://www.jahjournal.org/text.asp?2021/12/4/236/335936



A 56-year-old male presented with multiple swellings of varying size over the right leg with edema [Figure 1]. There was no lymphadenopathy. He had treatment with topical steroids, but the lesion progressed, so he underwent a skin biopsy. It showed an atypical mononuclear infiltrate. On immunohistochemistry, the cells were positive for CD20, B-cell lymphoma 2 (BCL-2), focally for MUM-1 and negative for CD10 and BCL-6. CD23 does not show any follicular dendritic cell (FDC) meshwork. Ki-67 index was 50%. These findings were consistent with primary cutaneous diffuse large BCL, leg type (PCDLBCL-LT). A whole-body 18F-fluorodeoxyglucose positron emission computed tomography (18F-FDG PET/CT) showed abnormal increased FDG uptake in multiple subcentimetric soft-tissue density seen surrounding the lower half of the right leg (SUV Max 10.5) [Figure 2]a. Follow-up evaluation by 18F-FDG PET/CT showed complete response after 4 cycles of combination chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) [Figure 2]b. Posttreatment (6 cycles of R-CHOP), he is on regular follow-up and is doing well for the past 6 years. PCDLBCL-LT is very rare accounting for <5% of all cutaneous lymphomas. PCDLBCL-LT usually affects elderly females (mean age: 70 years). They present with red to bluish nodules or tumors with or without ulceration on one or both lower legs. Only about 10%–15% of patients have lesions outside the lower extremities. They are more aggressive with worse outcomes. The prognosis of PCDLBCL-LT is poor, with a 5-year survival rate of 41%–58%. This case is unusual being a young male and with long-term survival.
Figure 1: Multiple cutaneous swellings of varying size over the right leg

Click here to view
Figure 2: (a) F-Fluorodeoxyglucose positron emission computed tomography showing abnormal increased fluorodeoxyglucose uptake in multiple subcentimetric soft-tissue density seen surrounding the lower part of the right leg. (b) Shows complete disappearance of fluorodeoxyglucose activity after 4 cycles of chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone

Click here to view


Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient (s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.




    Figures

  [Figure 1], [Figure 2]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Article Figures

 Article Access Statistics
    Viewed483    
    Printed14    
    Emailed0    
    PDF Downloaded71    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]